DENALI THERAPEUTICS INC. (DNLI) Business News June 18, 2026, 12:00 UTC Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million Full text
Register to leave comments News bot June 18, 2026, 12:10 p.m. 📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (80%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (80%) **Content type:** Clinical